Ambrisentan

Ambrisentan is a selective endothelin-1 type A (ETA) receptor antagonist indicated for the treatment of pulmonary arterial hypertension (PAH). It improves exercise capacity and delays clinical worsening. Mediocon Inc supplies pharmaceutical-grade Ambrisentan for licensed pharmaceutical manufacturers.

Key Features

• Selective ETA receptor antagonist
• USP/EP compliant quality
• Improves PAH exercise capacity
• Suitable for once-daily tablet formulations

Applications

• Pulmonary arterial hypertension tablets
• PAH combination therapy
• Functional class II–III PAH
• Specialty cardiovascular formulations

Why Choose Mediocon

• ISO 9001:2015 & GMP certified manufacturing
• Consistent batch-to-batch quality with full CoA
• Export-ready documentation: COO, MSDS, DMF
• Flexible MOQ for both R&D and commercial scale
• Dedicated QA support for regulatory filings